147 related articles for article (PubMed ID: 20010073)
1. Response to planned treatment interruptions in HIV infection varies across childhood.
Paediatric European Network for Treatment of AIDS
AIDS; 2010 Jan; 24(2):231-41. PubMed ID: 20010073
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.
Bunupuradah T; Duong T; Compagnucci A; McMaster P; Bernardi S; Kanjanavanit S; Rampon O; Faye A; Saïdi Y; Riault Y; De Rossi A; Klein N; Ananworanich J; Gibb D;
AIDS; 2013 Feb; 27(4):579-89. PubMed ID: 23135172
[TBL] [Abstract][Full Text] [Related]
3. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
[TBL] [Abstract][Full Text] [Related]
4. The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Klein N; Sefe D; Mosconi I; Zanchetta M; Castro H; Jacobsen M; Jones H; Bernardi S; Pillay D; Giaquinto C; Walker AS; Gibb DM; De Rossi A;
PLoS One; 2013; 8(10):e76582. PubMed ID: 24194841
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.
Freguja R; Bamford A; Zanchetta M; Del Bianco P; Giaquinto C; Harper L; Dalzini A; Cressey TR; Compagnucci A; Saidi Y; Riault Y; Ford D; Gibb D; Klein N; De Rossi A;
HIV Med; 2021 Mar; 22(3):172-184. PubMed ID: 33124144
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
8. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
Gibb DM; Duong T; Leclezio VA; Walker AS; Verweel G; Dunn DT;
Pediatr Infect Dis J; 2004 May; 23(5):446-50. PubMed ID: 15131469
[TBL] [Abstract][Full Text] [Related]
9. CD4 recovery following antiretroviral treatment interruptions in children and adolescents with HIV infection in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
HIV Med; 2019 Aug; 20(7):456-472. PubMed ID: 31099155
[TBL] [Abstract][Full Text] [Related]
10. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.
Pai NP; Tulsky JP; Lawrence J; Colford JM; Reingold AL
Cochrane Database Syst Rev; 2005 Oct; (4):CD005482. PubMed ID: 16235406
[TBL] [Abstract][Full Text] [Related]
11. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
DART Trial Team
AIDS; 2008 Jan; 22(2):237-47. PubMed ID: 18097226
[TBL] [Abstract][Full Text] [Related]
12. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
13. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.
Ananworanich J; Melvin D; Amador JT; Childs T; Medin G; Boscolo V; Compagnucci A; Kanjanavanit S; Montero S; Gibb DM;
AIDS; 2016 Apr; 30(7):1075-81. PubMed ID: 26730569
[TBL] [Abstract][Full Text] [Related]
14. Impact of CD4 T cell count on the outcome of planned treatment interruptions in early-treated human immunodeficiency virus-infected children.
Fortuny C; Noguera-Julian A; Alsina L; Bellido R; Sánchez E; Muñoz-Almagro C; Ruiz L; Jiménez R
Pediatr Infect Dis J; 2011 May; 30(5):435-8. PubMed ID: 21030884
[TBL] [Abstract][Full Text] [Related]
15. Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
Harrison L; Ananworanich J; Hamadache D; Compagnucci A; Penazzato M; Bunupuradah T; Mazza A; Ramos JT; Flynn J; Rampon O; Mellado Pena MJ; Floret D; Marczynska M; Puga A; Forcat S; Riault Y; Lallemant M; Castro H; Gibb DM; Giaquinto C;
AIDS Behav; 2013 Jan; 17(1):193-202. PubMed ID: 22584916
[TBL] [Abstract][Full Text] [Related]
16. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
[TBL] [Abstract][Full Text] [Related]
17. Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.
Sandgaard KS; Margetts B; Attenborough T; Gkouleli T; Adams S; Holm M; Gibb D; Gibbons D; Giaquinto C; De Rossi A; Bamford A; Palma P; Chain B; Gkazi AS; Klein N
Front Immunol; 2021; 12():643189. PubMed ID: 34475868
[TBL] [Abstract][Full Text] [Related]
18. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
19. Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.
Seoane E; Resino S; Moreno S; de Quiros JC; Moreno A; Rubio R; Gonzalez-García J; Arribas JR; Pulido F; Muñoz-Fernández MA
BMC Infect Dis; 2008 Feb; 8():20. PubMed ID: 18302775
[TBL] [Abstract][Full Text] [Related]
20. Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).
Piroth L; Moinot L; Yeni P; Avettand-Fénoel V; Reynes J; Girard PM; Marchou B; Georget A; Rouzioux C; Autran B; Duvillard L; Chêne G; Fagard C;
J Antimicrob Chemother; 2016 Feb; 71(2):490-6. PubMed ID: 26568566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
